Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study

<p><strong>Introduction</strong>&nbsp;People who sustain a hip fracture are typically elderly, frail and require urgent surgery. Hip fracture and the urgent surgery is associated with acute blood loss, compounding patients&rsquo; pre-existing comorbidities including anaemia...

Full description

Bibliographic Details
Main Authors: Dickenson, E, Griffin, XL, Achten, J, Mironov, K, O'Connor, H, Parsons, N, Murphy, M, Wyse, M, Mason, J, Appelbe, D, Athwal, A, Griffin, D
Format: Journal article
Language:English
Published: BMJ Publishing Group 2022
_version_ 1797111347483246592
author Dickenson, E
Griffin, XL
Achten, J
Mironov, K
O'Connor, H
Parsons, N
Murphy, M
Wyse, M
Mason, J
Appelbe, D
Athwal, A
Griffin, D
author_facet Dickenson, E
Griffin, XL
Achten, J
Mironov, K
O'Connor, H
Parsons, N
Murphy, M
Wyse, M
Mason, J
Appelbe, D
Athwal, A
Griffin, D
author_sort Dickenson, E
collection OXFORD
description <p><strong>Introduction</strong>&nbsp;People who sustain a hip fracture are typically elderly, frail and require urgent surgery. Hip fracture and the urgent surgery is associated with acute blood loss, compounding patients&rsquo; pre-existing comorbidities including anaemia. Approximately 30% of patients require a donor blood transfusion in the perioperative period. Donor blood transfusions are associated with increased rates of infections, allergic reactions and longer lengths of stay. Furthermore, there is a substantial cost associated with the use of donor blood. Cell salvage and autotransfusion is a technique that recovers, washes and transfuses blood lost during surgery back to the patient. The objective of this study is to determine the clinical and cost effectiveness of intraoperative cell salvage, compared with standard care, in improving health related quality-of-life of patients undergoing hip fracture surgery.</p> <p><strong>Methods and analysis</strong>&nbsp;Multicentre, parallel group, two-arm, randomised controlled trial. Patients aged 60 years and older with a hip fracture treated with surgery are eligible. Participants will be randomly allocated on a 1:1 basis to either undergo cell salvage and autotransfusion or they will follow the standard care pathway. Otherwise, all care will be in accordance with the National Institute for Health and Care Excellence guidance. A minimum of 1128 patients will be recruited to obtain 90% power to detect a 0.075-point difference in the primary endpoint: EuroQol-5D-5L HRQoL at 4&thinsp;months post injury. Secondary outcomes will include complications, postoperative delirium, residential status, mobility, allogenic blood use, mortality and resource use.</p> <p><strong>Ethics and dissemination</strong>&nbsp;NHS ethical approval was provided on 14 August 2019 (19/WA/0197) and the trial registered (ISRCTN15945622). After the conclusion of this trial, a manuscript will be prepared for peer-review publication. Results will be disseminated in lay form to participants and the public.</p> <p><strong>Trial registration number</strong>&nbsp;ISRCTN15945622.</p>
first_indexed 2024-03-07T08:09:04Z
format Journal article
id oxford-uuid:17be921c-98b0-44fa-8174-7df1f3d3f929
institution University of Oxford
language English
last_indexed 2024-03-07T08:09:04Z
publishDate 2022
publisher BMJ Publishing Group
record_format dspace
spelling oxford-uuid:17be921c-98b0-44fa-8174-7df1f3d3f9292023-11-17T06:37:31ZRandomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:17be921c-98b0-44fa-8174-7df1f3d3f929EnglishSymplectic ElementsBMJ Publishing Group2022Dickenson, EGriffin, XLAchten, JMironov, KO'Connor, HParsons, NMurphy, MWyse, MMason, JAppelbe, DAthwal, AGriffin, D<p><strong>Introduction</strong>&nbsp;People who sustain a hip fracture are typically elderly, frail and require urgent surgery. Hip fracture and the urgent surgery is associated with acute blood loss, compounding patients&rsquo; pre-existing comorbidities including anaemia. Approximately 30% of patients require a donor blood transfusion in the perioperative period. Donor blood transfusions are associated with increased rates of infections, allergic reactions and longer lengths of stay. Furthermore, there is a substantial cost associated with the use of donor blood. Cell salvage and autotransfusion is a technique that recovers, washes and transfuses blood lost during surgery back to the patient. The objective of this study is to determine the clinical and cost effectiveness of intraoperative cell salvage, compared with standard care, in improving health related quality-of-life of patients undergoing hip fracture surgery.</p> <p><strong>Methods and analysis</strong>&nbsp;Multicentre, parallel group, two-arm, randomised controlled trial. Patients aged 60 years and older with a hip fracture treated with surgery are eligible. Participants will be randomly allocated on a 1:1 basis to either undergo cell salvage and autotransfusion or they will follow the standard care pathway. Otherwise, all care will be in accordance with the National Institute for Health and Care Excellence guidance. A minimum of 1128 patients will be recruited to obtain 90% power to detect a 0.075-point difference in the primary endpoint: EuroQol-5D-5L HRQoL at 4&thinsp;months post injury. Secondary outcomes will include complications, postoperative delirium, residential status, mobility, allogenic blood use, mortality and resource use.</p> <p><strong>Ethics and dissemination</strong>&nbsp;NHS ethical approval was provided on 14 August 2019 (19/WA/0197) and the trial registered (ISRCTN15945622). After the conclusion of this trial, a manuscript will be prepared for peer-review publication. Results will be disseminated in lay form to participants and the public.</p> <p><strong>Trial registration number</strong>&nbsp;ISRCTN15945622.</p>
spellingShingle Dickenson, E
Griffin, XL
Achten, J
Mironov, K
O'Connor, H
Parsons, N
Murphy, M
Wyse, M
Mason, J
Appelbe, D
Athwal, A
Griffin, D
Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study
title Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study
title_full Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study
title_fullStr Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study
title_full_unstemmed Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study
title_short Randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study
title_sort randomised controlled trial comparing intraoperative cell salvage and autotransfusion with standard care in the treatment of hip fractures a protocol for the white 9 study
work_keys_str_mv AT dickensone randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT griffinxl randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT achtenj randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT mironovk randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT oconnorh randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT parsonsn randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT murphym randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT wysem randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT masonj randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT appelbed randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT athwala randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study
AT griffind randomisedcontrolledtrialcomparingintraoperativecellsalvageandautotransfusionwithstandardcareinthetreatmentofhipfracturesaprotocolforthewhite9study